


Status: Currently Official on 16-Feb-2025  
 Official Date: Official as of 01-May-2020  
 Document Type: USP Monographs  
 DocId: GUID-1AEE6B36-CCC0-4A8D-AB74-4516C5ADDBBC\_4\_en-US  
 DOI: [https://doi.org/10.31003/USPNF\\_M62430\\_04\\_01](https://doi.org/10.31003/USPNF_M62430_04_01)  
 DOI Ref: z8yra

© 2025 USPC  
 Do not distribute

## Pentoxifylline



$C_{13}H_{18}N_4O_3$  278.31

1*H*-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)-;

1-(5-Oxohexyl)theobromine CAS RN®: 6493-05-6.

### DEFINITION

Pentoxifylline contains NLT 98.0% and NMT 102.0% of pentoxifylline ( $C_{13}H_{18}N_4O_3$ ).

### IDENTIFICATION

#### Change to read:

- **A.** ▲ [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), [Infrared Spectroscopy: 197K](#) ▲ (CN 1-MAY-2020)
- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

### ASSAY

#### PROCEDURE

**Solution A:** 1 g/L of perchloric acid

**Mobile phase:** Methanol, tetrahydrofuran, acetonitrile, and *Solution A* (2:2.5:15:80)

**System suitability solution:** 0.024 mg/mL of caffeine and 0.048 mg/mL of [USP Pentoxifylline RS](#) in *Mobile phase*

**Standard solution:** 0.05 mg/mL of [USP Pentoxifylline RS](#) in *Mobile phase*

**Sample solution:** 0.05 mg/mL of Pentoxifylline in *Mobile phase*

#### Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

**Mode:** LC

**Detector:** UV 273 nm

**Column:** 4.6-mm × 25-cm; 5-μm packing L1

**Flow rate:** 0.7 mL/min

**Injection volume:** 10 μL

#### System suitability

**Samples:** *System suitability solution* and *Standard solution*

#### Suitability requirements

**Resolution:** NLT 10.0 between caffeine and pentoxifylline, *System suitability solution*

**Relative standard deviation:** NMT 2.0%, *Standard solution*

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of pentoxifylline ( $C_{13}H_{18}N_4O_3$ ) in the portion of Pentoxifylline taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response from the *Sample solution*

$r_S$  = peak response from the *Standard solution*

$C_s$  = concentration of [USP Pentoxifylline RS](#) in the *Standard solution* (mg/mL)

$C_u$  = concentration of Pentoxifylline in the *Sample solution* (mg/mL)

**Acceptance criteria:** 98.0%–102.0%

#### IMPURITIES

- [RESIDUE ON IGNITION \(281\)](#): NMT 0.1%

- [CHLORIDE AND SULFATE, Chloride\(221\)](#).

**Sample:** 2.0 g

**Acceptance criteria:** The *Sample* shows no more chloride than corresponds to 0.31 mL of 0.020 N hydrochloric acid (0.011%).

- [CHLORIDE AND SULFATE, Sulfate\(221\)](#).

**Sample:** 1.0 g

**Acceptance criteria:** The *Sample* shows no more sulfate than corresponds to 0.20 mL of 0.020 N sulfuric acid (0.02%).

- **ORGANIC IMPURITIES**

**Solution A and Mobile phase:** Prepare as directed in the Assay.

**System suitability solution:** 0.7 µg/mL of caffeine and 350 µg/mL of [USP Pentoxifylline RS](#) in *Mobile phase*

**Standard solution:** 0.7 µg/mL of [USP Pentoxifylline RS](#) in *Mobile phase*

**Sample solution:** 350 µg/mL of Pentoxifylline in *Mobile phase*

**Chromatographic system:** Proceed as directed in the Assay except for the following:

**Injection volume:** 20 µL

**Run time:** NLT 5 times the retention time for pentoxifylline

#### System suitability

**Samples:** *System suitability solution* and *Standard solution*

#### Suitability requirements

**Resolution:** NLT 10.0 between caffeine and pentoxifylline, *System suitability solution*

**Relative standard deviation:** NMT 5.0%, *Standard solution*

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Measure the areas of all the peaks in the *Sample solution*, except for that of pentoxifylline.

Calculate the percentage of each impurity in the portion of Pentoxifylline taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

$r_u$  = peak response of each impurity from the *Sample solution*

$r_s$  = peak response of pentoxifylline from the *Standard solution*

$C_s$  = concentration of [USP Pentoxifylline RS](#) in the *Standard solution* (µg/mL)

$C_u$  = concentration of Pentoxifylline in the *Sample solution* (µg/mL)

#### Acceptance criteria

**Individual impurities:** NMT 0.2%

**Total impurities:** NMT 0.5%

#### SPECIFIC TESTS

- [COMPLETENESS OF SOLUTION \(641\)](#).

**Sample solution:** 1 g in 50 mL of carbon dioxide-free water

**Acceptance criteria:** Meets the requirements

- **ACIDITY**

**Sample solution:** 1 g in 50 mL of carbon dioxide-free water

**Analysis:** To the *Sample solution* add 1 drop of bromothymol blue TS.

**Acceptance criteria:** NMT 0.2 mL of 0.01 N sodium hydroxide is required to produce a color change.

- [LOSS ON DRYING \(731\)](#).

**Analysis:** Dry under vacuum at 60° for 3 h.

**Acceptance criteria:** NMT 0.5%

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in well-closed containers.
- **USP REFERENCE STANDARDS** (11).  
[USP Pentoxifylline RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
PENTOXIFYLLINE	<a href="#">Documentary Standards Support</a>	SM22020 Small Molecules 2
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM22020 Small Molecules 2

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:  
Pharmacopeial Forum: Volume No. PF 39(4)

Current DocID: GUID-1AEE6B36-CCC0-4A8D-AB74-4516C5ADDBBC\_4\_en-US

DOI: [https://doi.org/10.31003/USPNF\\_M62430\\_04\\_01](https://doi.org/10.31003/USPNF_M62430_04_01)

DOI ref: [z8yra](#)

OFFICIAL